Edition:
India

Bellicum Pharmaceuticals Inc (BLCM.OQ)

BLCM.OQ on NASDAQ Stock Exchange Global Market

9.99USD
2:29am IST
Change (% chg)

$0.37 (+3.85%)
Prev Close
$9.62
Open
$9.61
Day's High
$10.06
Day's Low
$9.58
Volume
67,319
Avg. Vol
161,181
52-wk High
$22.92
52-wk Low
$7.42

Latest Key Developments (Source: Significant Developments)

Bellicum reports qtrly earnings per share loss‍ $0.71​
Wednesday, 8 Nov 2017 

Nov 7 (Reuters) - Bellicum Pharmaceuticals Inc ::Bellicum reports third quarter 2017 financial results.Bellicum Pharmaceuticals Inc qtrly earnings per share loss‍ $0.71​.Q3 earnings per share view $-0.74 -- Thomson Reuters I/B/E/S.  Full Article

Bellicum announces appointment of Rick Fair as CEO
Tuesday, 31 Jan 2017 

Bellicum Pharmaceuticals Inc : Bellicum announces appointment of Rick Fair as chief executive officer in preparation for commercialization of bpx-501 and next phase of growth . Bellicum pharmaceuticals - fair joins Bellicum from Genentech/Roche, where he was senior vice president, head of oncology global product strategy .Bellicum Pharmaceuticals Inc - Fair succeeds Tom Farrell, who will serve as an advisor to company during transition.  Full Article

Biolife solutions executes 10 year supply agreement with Bellicum Pharmaceuticals for CryoStor use in cellular immunotherapies
Wednesday, 10 Aug 2016 

BioLife Solutions Inc :Biolife solutions executes 10 year supply agreement with Bellicum Pharmaceuticals for CryoStor® use in cellular immunotherapies.  Full Article

Bellicum qtrly loss per share $0.61
Tuesday, 9 Aug 2016 

Bellicum Pharmaceuticals Inc : Bellicum pharmaceuticals reports second quarter 2016 financial results and provides corporate update .Qtrly loss per share $0.61.  Full Article

Bellicum Pharmaceuticals Inc says FDA grants orphan drug designation to Bellicum's BPX-501 for treatment of immunodeficiency and GvHD following stem cell
Monday, 22 Feb 2016 

Bellicum Pharmaceuticals Inc:Says FDA grants orphan drug designation to Bellicum's BPX-501 for treatment of immunodeficiency and GvHD following stem cell.  Full Article